CRUK

Abcam will develop custom protein-based reagents for targets identified by researchers funded by Cancer Research UK. 

ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).

Researchers from the TRACERx consortium analyzed blood and tumor samples to tease out features of lung cancers that are more likely to recur.

Concordance numbers and early evidence of clinical impact from a 100-patient first phase were sufficient to expand to another 450 individuals.

Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.